Patient P-01733

Synthetic patientNBL-101 · Day 101 · 55–64 · M · baseline S05Open companion preview

Therapy response

Improving

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S05
Day 45 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 54 SC-12 recommended — Supportive Compound SC-12
Day 55 Patient accepted — Started SC-12 in the companion
Day 61 No meaningful change — Supportive Compound SC-12

What changed?

Trajectory began diverging from predicted response on Day 45.

Primary contributors, last 14 days

GI instability+13
Nutritional resilience-12
Treatment adherence+5
Inflammatory activity+4
Toxicity+3

What helped?

Supportive Compound SC-12Day 54
Result: no meaningful change

LIFE OS recommendation

GI Support Protocol GI-04

90%

probability of meaningful tolerance improvement

284 similar trajectories
84% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 69 and rising
- WearableSleep 5.4 h, below personal baseline
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 36/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓65
- WearableResting HR 80 bpm
- Wearable3,379 steps/day
- WearableShort sleep window
Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 49
Inflammatory signalling ↑25
- BloodInflammatory load index 63

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Poor metabolizer
Higher exposure at standard dose

Microbiome

Shannon diversity 3 · butyrate capacity 36/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 46 ms
Sleep: 5.3 h
Steps: 1,471
Resting HR: 79 bpm

Daily log: GI score 69, nutritional resilience 30, adherence 42.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01843	50%	S14	SC-12	no change	45
P-01732	49%	S14	ME-01	improved	45
P-01328	47%	S14	SC-12	no change	49
P-01311	46%	S14	ME-01	improved	49
P-01751	46%	S14	ME-01	improved	48
P-01554	45%	S05	GI-04	improved	47
P-01646	45%	S14	GI-04	no change	42
P-01656	45%	S14	ME-01	improved	41
P-01360	44%	S14	GI-04	improved	52
P-01463	44%	S14	NP-02	no change	41
P-01735	44%	S14	—	—	40
P-01799	44%	S19	NP-02	no change	51